New AI vaccine developed
Vaxin has now developed a vaccine that can be rapidly
produced and mass administered. This vaccine was recently featured at the
Immunotherapeutics & Vaccine Summit in Boston.
Kent Van Kampen, Vaxin's COO and an authority on vaccine development: "Our
vaccine uses a neutered cold virus to carry a tiny snippet of influenza DNA,
rather than the entire influenza virus," Van Kampen said. "When the immune
system responds, it actually learns how to be immune to the target disease -
avian influenza in this case."
This vaccine has been shown to provide excellent protection when
administered to poultry before hatching. Vaxin has utilised these advances to
develop a version of the vaccine that will soon be tested in humans.
To comment, login here
Or register to be able to comment.